183 related articles for article (PubMed ID: 31707687)
21. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
[TBL] [Abstract][Full Text] [Related]
22. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
[TBL] [Abstract][Full Text] [Related]
25. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Mason WP; Macneil M; Kavan P; Easaw J; Macdonald D; Thiessen B; Urva S; Lwin Z; McIntosh L; Eisenhauer E
Invest New Drugs; 2012 Dec; 30(6):2344-51. PubMed ID: 22160854
[TBL] [Abstract][Full Text] [Related]
27. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
[TBL] [Abstract][Full Text] [Related]
29. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK; Reardon DA; Lassman AB; Merrell R; van den Bent M; Butowski N; Lwin Z; Wheeler H; Fichtel L; Scott AM; Gomez EJ; Fischer J; Mandich H; Xiong H; Lee HJ; Munasinghe WP; Roberts-Rapp LA; Ansell PJ; Holen KD; Kumthekar P
Neuro Oncol; 2018 May; 20(6):838-847. PubMed ID: 29077941
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Nghiemphu PL; Wen PY; Lamborn KR; Drappatz J; Robins HI; Fink K; Malkin MG; Lieberman FS; DeAngelis LM; Torres-Trejo A; Chang SM; Abrey L; Fine HA; Demopoulos A; Lassman AB; Kesari S; Mehta MP; Prados MD; Cloughesy TF;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1422-7. PubMed ID: 20934264
[TBL] [Abstract][Full Text] [Related]
31. A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
Kleinberg L; Ye X; Supko J; Stevens GHJ; Shu HK; Mikkelsen T; Lieberman F; Lesser GJ; Lee E; Grossman SA
J Neurooncol; 2023 Dec; 165(3):499-507. PubMed ID: 38015376
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
33. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
[TBL] [Abstract][Full Text] [Related]
34. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Elinzano H; Toms S; Robison J; Mohler A; Carcieri A; Cielo D; Donnelly J; Disano D; Vatketich J; Baekey J; Sturtevant A; MacKinnon K; Wood R; Safran H
Am J Clin Oncol; 2021 Feb; 44(2):49-52. PubMed ID: 33284237
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
36. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
38. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Maraka S; Groves MD; Mammoser AG; Melguizo-Gavilanes I; Conrad CA; Tremont-Lukats IW; Loghin ME; O'Brien BJ; Puduvalli VK; Sulman EP; Hess KR; Aldape KD; Gilbert MR; de Groot JF; Alfred Yung WK; Penas-Prado M
Cancer; 2019 Feb; 125(3):424-433. PubMed ID: 30359477
[TBL] [Abstract][Full Text] [Related]
40. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]